Loading...
•
Dec 31, 2021
Janux Q4 2021 Earnings Report
Janux reported Q4 2021 financial results and provided a business update.
Key Takeaways
Janux Therapeutics reported cash, cash equivalents and short-term investments of $375.0 million. Research and development expenses were $11.2 million. Net loss was $13.4 million for the quarter.
Company remains on-track to submit IND filings for two programs in 2022
Company nominated its first TRACIr development candidate, a PD-L1 x CD28 costimulatory bispecific
Management team strengthened with key appointment
$375.0 million in year-end 2021 cash, cash equivalents and short-term investments
Forward Guidance
Janux expects to submit an IND for its PSMA-TRACTr candidate in the first half of 2022 and an IND application for its EGFR-TRACTr candidate in the second half of 2022. In 2023, Janux expects to submit an IND application for its TROP2-TRACTr and PD-L1xCD28 programs.
Positive Outlook
- Janux expects to submit an IND for its PSMA-TRACTr candidate in the first half of 2022
- Janux expects to submit an IND application for its EGFR-TRACTr candidate in the second half of 2022
- Janux expects to submit an IND application for its TROP2-TRACTr in 2023
- Janux expects to submit an IND application for its PD-L1xCD28 programs in 2023
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...